For many years, doctors did not know what really caused cervical cancer. Dr. zur Hausen focused on HPV, a DNA virus, instead of the previously suspected herpes viruses. He detected new types, HPV-16 and HPV-18, in tumor cells and showed that their DNA integrates into human chromosomes. Viral proteins E6 and E7 disable the tumor-suppressor genes p53 and Rb, pushing cells to divide forever. Later studies proved that HPV spreads mainly through sexual contact, and that persistent—not short-lived—infection is dangerous. DNA testing and vaccination are now global prevention tools and have already reduced cancer rates. His work became a textbook example of virus-cancer links and has huge social impact. It also clarified the role of HPV in other cancers such as oropharyngeal and anal tumors.

Human papillomaviruses (HPVs) are ~55-nm double-stranded DNA viruses whose replication depends on epithelial cell differentiation. zur Hausen combined low-stringency hybridization with molecular cloning—an innovative approach for an uncultivable pathogen—and isolated the full genomes of HPV-16 and HPV-18 from tumors. He demonstrated that the same viral DNA is present in a large fraction of cervical cancers worldwide. In patient samples, only parts of the viral genome are integrated; replication genes E1/E2 are disrupted, whereas oncogenes E6/E7 are retained and highly expressed. E6 teams with E6AP to ubiquitinate and degrade p53, and E7 binds the Rb family, liberating E2F and forcing G1-to-S transition. Cell and animal models confirmed that these mechanisms drive progression from cervical intraepithelial neoplasia (CIN) to invasive cancer. Epidemiology shows that high-risk HPV is detectable in about 99% of cervical cancers, fulfilling causal criteria. Virus-like-particle vaccines based on the L1 capsid protein induce strong neutralizing antibodies and cut HPV16/18-related precancerous lesions by over 70%. Yet types not covered by current vaccines persist, making combined DNA testing and cytology screening still vital. HPV research has advanced our understanding of viral oncogenesis, genome instability, and host immunity, influencing studies on EBV, HBV, and others. Phylogenetic analyses now model type-specific natural history and herd-immunity effects. These insights feed directly into public-health policy, price negotiations, and vaccination programs in low-resource settings, illustrating bench-to-implementation success.

After cloning HPV16/18, zur Hausen’s team identified tumor-specific fusion bands by Southern blot, proving monoclonal viral integration. Frequent disruption of the E2 ORF in integrated genomes releases transcriptional repression of E6/E7. siRNA knock-down of E6/E7 triggers apoptosis in HeLa and SiHa cells, supporting the concept of viral-oncogene addiction. Long-range PCR and NGS mapping reveal preferential integration at fragile sites and actively transcribed loci in the host genome. Beyond p53/Rb interference, persistent E6/E7 expression chronically activates ATR/CHK1 and drives replication-stress DNA-damage responses. Proteomics shows E6 targeting of PDZ-domain proteins and the TERT promoter, coupling chromosomal instability with telomerase activation. In VLP vaccine design, baculovirus-derived L1 self-assembly and adjuvant optimization proved critical for high-titer neutralizing antibodies and durable B-cell memory. Therapeutic vaccines and CRISPR/Cas strategies to eliminate latent HPV remain pre-clinical. Comparative genomics of HPV variants suggests co-evolution with host HLA haplotypes, urging reassessment of cross-protective vaccine breadth. Integrating metagenomics with real-world clinical outcomes is expected to speed next-generation prevention strategies.